Healthcare / BiotechnologyTaipei Exchange
$25.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-69.9M · quality 56.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-35.7%
↓Gross Margin
60.1%
↑Debt/Equity
0.65
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.0%
FCF CAGR
—
FCF margin
-39.0%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $179.5M · net income $-85.6M · FCF $-69.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $179.5M | $179.5M | $189.8M | $231.8M | $184.8M |
| Net Income | $-85.6M | $-85.6M | $-94.4M | $-47.4M | $-50.1M |
| EBITDA | $-55.5M | $-55.5M | $-62.9M | $-12.6M | $-10.9M |
| EPS | — | — | -2.38 | -1.28 | -1.35 |
| Gross Margin | 60.1% | 60.1% | 59.6% | 57.8% | 53.0% |
| Operating Margin | -45.2% | -45.2% | -48.4% | -18.8% | -26.3% |
| Net Margin | -47.7% | -47.7% | -49.7% | -20.4% | -27.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.65 | 0.65 | 0.35 | 0.45 | 0.34 |
| Current Ratio | 0.80 | 0.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-69.9M | $-69.9M | $-77.3M | $-14.4M | $-10.4M |
| Returns | |||||
| ROE | -35.7% | -35.7% | -29.0% | -16.9% | -15.3% |
| Valuation | |||||
| P/B | 4.35 | 4.35 | 3.59 | 3.82 | 3.62 |
| Growth & Yield | |||||
| Revenue Growth | -5.4% | -5.4% | -18.1% | 25.5% | — |
| EPS Growth | — | — | -85.9% | 5.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.38 → n/d
Residual
-0.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.